Less Ads, More Data, More Tools Register for FREE

Friday broker round-up

Fri, 17th Feb 2017 09:19
(ShareCast News) - AstraZeneca: Jefferies reiterates Buy with a target price of 5250p.BT Group: Jefferies reiterates Hold with a target price of 325p.Standard Life: Macquarie reiterates Outperform with a target price of 450p.Cobham: Goldman Sachs reiterates Sell with a target price of 88p.Drax: JPMorgan reiterates Overweight with a target price of 410p.South32: Deutsche Bank reiterates Hold with a target price of 157p.Royal Dutch Shell: UBS reiterates Buy with a target price of 2500p.AstraZeneca: Shore reiterates Sell with a target price of 4525p.Kenmare Resources: Canaccord maintains Buy with a target price of 510p.UNITE Group: Numis reiterates Buy with a target price of 731p. Astrazeneca South32 Limited Drax BT Unite Kenmare Resources

Shares in this article

Related News

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
13 hours ago

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

* Deal deepens oncology push under CEO Luke Miels

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
18 hours ago

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

* Deal deepens oncology push under CEO Luke Miels

Pfizer CEO warns German investment at risk over drug pricing policies
1 day ago

Pfizer CEO warns German investment at risk over drug pricing policies

LONDON/FRANKFURT, June 10 (Reuters) - ​Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter ...

Pharmaceuticals Pfizer + 3 more shares